Gujarat Kidney & Super Speciality Ltd shareholders unanimously approved all twelve resolutions passed during its seventh Annual General Meeting (AGM) held on September 28, 2026. The meeting, conducted via poll and remote e-voting, covered the adoption of FY26 financial statements, director appointments, and operational authorizations.

The proceedings complied with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scrutinizer’s report confirmed that all resolutions set out in the notice dated August 24, 2026, were passed with the requisite majority. The meeting concluded at 9:50 am at the company’s registered office in Vadodara.

Voting results for key resolutions

Remote e-voting was open from September 25 to September 27, 2026. A total of 57,047,371 votes were cast in favor of the adoption of standalone and consolidated financial statements for FY26, representing 99.9984% of valid votes through e-voting. Only two members voted against this resolution, accounting for 898 votes or 0.0016% of the total.

The appointment of new independent directors, Mr Paresh Dhoti and Mrs Disha Bharpoda, received 100% support from remote voters, with 57,046,305 votes cast in favor. Similarly, the re-appointment of Mrs Anita Bharpoda as a director retiring by rotation secured unanimous approval from both remote and physical voters.

Governance and remuneration approvals

Shareholders approved revisions to the remuneration of Managing Director Pragnesh Bharpoda and Wholetime Director Bharti Bharpoda. These changes reflect updated compensation structures aligned with company performance. The board also authorized the engagement of secretarial auditors and ratified related party transactions.

Notably, for the resolution approving related party transactions, 13 members voted in favor via remote e-voting, casting 203,230 votes. However, six members’ votes totaling 56,843,075 were declared invalid for this specific item, likely due to conflict of interest rules requiring abstention by interested parties.

Operational and borrowing powers

The AGM granted several operational approvals under the Companies Act, 2013. These included authorizations under Section 180(1)(a) and Section 180(1)(c), relating to borrowing powers and investment limits. The board also secured approval to increase thresholds for loans, guarantees, securities, and investments under Section 186, as well as permissions to advance loans or provide security under Section 185.

Meeting attendance and quorum

The meeting was attended by key management personnel, including Chairman and Managing Director Pragnesh Bharpoda, Wholetime Director Bharti Pragnesh Bharpoda, and Non-Executive Non-Independent Director Anita Bharpoda. Independent directors Jagdish Thakkar, Udayan Kachchi, and Dr Kairavi Shah were present, along with Chief Financial Officer Bhavika Patel and Company Secretary Vishakha Phadke. Representatives from statutory and secretarial auditors, along with the scrutinizer, were also in attendance.

Gujarat Kidney and Superspeciality reported a 14% increase in standalone revenue to ₹4,010.02 lakh for the fiscal year ended March 31, 2026. Standalone profit after tax rose 8.7% to ₹990.14 lakh from ₹910.90 lakh in the previous year.

The company consolidated its expansion through an Initial Public Offering (IPO) that raised ₹250.80 crore in December 2025. Consolidated revenue more than doubled to ₹8,201.34 lakh, driven by acquisitions of Harmony Medicare, Parekhs Hospital, and other entities during the year.

Financial Performance

Standalone profit before tax grew 3.7% to ₹1,254.70 lakh. Total expenses rose to ₹2,804.77 lakh from ₹2,318.43 lakh, reflecting higher professional fees and expected credit losses.

Consolidated net profit attributable to owners of the company reached ₹1,549.69 lakh, up from ₹941.31 lakh in FY25. The group recorded total comprehensive income of ₹1,678.22 lakh.

IPO Utilization

The company utilized ₹190.23 crore of the ₹250.80 crore raised through the IPO as of March 31, 2026. Funds were deployed for acquiring Parekhs Hospital (₹77.00 crore), Ashwini Medical Centre (₹12.40 crore), and additional stake in Harmony Medicare (₹10.78 crore). ₹74.82 crore was used for inorganic growth and general corporate purposes.

What the Numbers Show

While standalone revenue grew steadily at 14%, the consolidated revenue surge to over ₹8,200 lakh indicates significant contribution from newly acquired entities. The acquisition of goodwill totaling ₹9,073.21 lakh on a consolidated basis suggests premium valuations paid for these hospital chains. Operating cash flow from standalone activities turned negative at -₹745.86 lakh, primarily due to a ₹607.78 lakh increase in trade receivables, signaling potential collection pressure amidst rapid expansion.